Search Results
You are looking at 1 - 3 of 3 items for :
- Author: Robin Peeters x
- Thyroid hormone action x
Search for other papers by Sander Barnhoorn in
Google Scholar
PubMed
Search for other papers by Marcel E Meima in
Google Scholar
PubMed
Search for other papers by Robin P Peeters in
Google Scholar
PubMed
Search for other papers by Veerle M Darras in
Google Scholar
PubMed
Search for other papers by Selmar Leeuwenburgh in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Oncode Institute, Utrecht, The Netherlands
Institute for Genome Stability in Ageing and Disease, CECAD Research Centre, Cologne, Germany
Search for other papers by Jan H J Hoeijmakers in
Google Scholar
PubMed
Oncode Institute, Utrecht, The Netherlands
Search for other papers by Wilbert P Vermeij in
Google Scholar
PubMed
Search for other papers by W Edward Visser in
Google Scholar
PubMed
Background
Thyroid hormone signaling is essential for development, metabolism, and response to stress but declines during aging, the cause of which is unknown. DNA damage accumulating with time is a main cause of aging, driving many age-related diseases. Previous studies in normal and premature aging mice, due to defective DNA repair, indicated reduced hepatic thyroid hormone signaling accompanied by decreased type 1 deiodinase (DIO1) and increased DIO3 activities. We investigated whether aging-related changes in deiodinase activity are driven by systemic signals or represent cell- or organ-autonomous changes.
Methods
We quantified liver and plasma thyroid hormone concentrations, deiodinase activities and expression of T3-responsive genes in mice with a global, liver-specific and for comparison brain-specific inactivation of Xpg, one of the endonucleases critically involved in multiple DNA repair pathways.
Results
Both in global and liver-specific Xpg knockout mice, hepatic DIO1 activity was decreased. Interestingly, hepatic DIO3 activity was increased in global, but not in liver-specific Xpg mutants. Selective Xpg deficiency and premature aging in the brain did not affect liver or systemic thyroid signaling. Concomitant with DIO1 inhibition, Xpg −/− and Alb-Xpg mice displayed reduced thyroid hormone-related gene expression changes, correlating with markers of liver damage and cellular senescence.
Conclusions
Our findings suggest that DIO1 activity during aging is predominantly modified in a tissue-autonomous manner driven by organ/cell-intrinsic accumulating DNA damage. The increase in hepatic DIO3 activity during aging largely depends on systemic signals, possibly reflecting the presence of circulating cells rather than activity in hepatocytes.
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Patrice Rodien in
Google Scholar
PubMed
Endocrine Section, Beacon Hospital, Dublin, Ireland.
School of Medicine, University College Dublin, Ireland
Endocrinology Department, St Vincent’s University Hospital, Dublin, Ireland
Search for other papers by Carla Moran in
Google Scholar
PubMed
Search for other papers by W Edward Visser in
Google Scholar
PubMed
Search for other papers by Stefan Groeneweg in
Google Scholar
PubMed
Search for other papers by Robin Peeters in
Google Scholar
PubMed
Search for other papers by Samuel Refetoff in
Google Scholar
PubMed
Search for other papers by Mark Gurnell in
Google Scholar
PubMed
Search for other papers by Paolo Beck-Peccoz in
Google Scholar
PubMed
Search for other papers by Krishna Chatterjee in
Google Scholar
PubMed
Impaired sensitivity to thyroid hormones encompasses disorders with defective transport of hormones into cells, reduced hormone metabolism, and resistance to hormone action. Mediated by heritable single-gene defects, these rare conditions exhibit different patterns of discordant thyroid function associated with multisystem phenotypes. In this context, challenges include ruling out other causes of biochemical discordance, making a diagnosis using clinical features together with the identification of pathogenic variants in causal genes, and managing these rare disorders with a limited evidence base. For each condition, the present guidelines aim to inform clinical practice by summarizing key clinical features and useful investigations, criteria for molecular genetic diagnosis, and pathways for management and therapy. Specific, key recommendations were developed by combining the best research evidence available with the knowledge and clinical experience of panel members, to achieve a consensus.
Search for other papers by Zhongli Chen in
Google Scholar
PubMed
Search for other papers by Robin P Peeters in
Google Scholar
PubMed
Search for other papers by Wesley Flach in
Google Scholar
PubMed
Search for other papers by Linda J de Rooij in
Google Scholar
PubMed
Search for other papers by Sena Yildiz in
Google Scholar
PubMed
DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany
Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
Search for other papers by Alexander Teumer in
Google Scholar
PubMed
Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Germany
Search for other papers by Matthias Nauck in
Google Scholar
PubMed
Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Rosalie B T M Sterenborg in
Google Scholar
PubMed
Search for other papers by Joost H W Rutten in
Google Scholar
PubMed
Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Marco Medici in
Google Scholar
PubMed
Search for other papers by W Edward Visser in
Google Scholar
PubMed
Search for other papers by Marcel E Meima in
Google Scholar
PubMed
Objective
Thyroid hormone (TH) transport represents a critical first step in governing intracellular TH regulation. It is still unknown whether the full repertoire of TH transporters has been identified. Members of the solute carrier (SLC) 22 family have substrates in common with the known TH transporters of the organic anion-transporting peptide family. Therefore, we screened the SLC22 family for TH transporters
Methods
Uptake of 1 nM of iodothyronines or sulfated iodothyronines in COS1 cells expressing SLC22 proteins was performed.
Results
We first tested 25 mouse (m) SLC22 proteins for TH uptake and found that the majority of the organic anion transporter (OAT) clade were capable of 3,3’,5-triiodothyronine and/or thyroxine (T4) transport. Based on phylogenetic tree analysis of the mouse and human (h) SLC22 family, we selected eight hSLC22s that grouped with the newly identified mouse TH transporters. Of these, four tested positive for uptake of one or more substrates, particularly hSLC22A11 showed robust (3-fold over control) uptake of T4. Uptake of sulfated iodothyronines was strongly (up to 17-fold) induced by some SLC22s, most notably SLC22A8, hSLC22A9, mSLC22A27 and mSLC22A29. Finally, the zebrafish orthologues of SLC22A6/8 drOatx and drSlc22a6l also transported almost all (sulfated) iodothyronines tested. The OAT inhibitors lesinurad and probenecid inhibited most SLC22 proteins.
Conclusions
Our results demonstrated that members of the OAT clade of the SLC22 family constitute a novel, evolutionary conserved group of transporters for (sulfated) iodothyronines. Future studies should reveal the relevance of these transporters in TH homeostasis and physiology.